CORT Profile
Corcept Therapeutics Incorporated, based in Menlo Park, California, specializes in the discovery, development, and commercialization of pharmaceuticals targeting severe metabolic, oncologic, and neuropsychiatric disorders within the United States. The company's flagship product, Korlym (mifepristone) tablets, serves as a once-daily oral medication designed to alleviate hyperglycemia secondary to hypercortisolism in adult patients afflicted with endogenous Cushing's syndrome. This treatment option is particularly suited for individuals managing type 2 diabetes mellitus or glucose intolerance, who have either undergone unsuccessful surgery or are deemed unsuitable candidates for surgical intervention.
In addition to Korlym, Corcept Therapeutics is actively advancing its pipeline with promising candidates such as relacorilant. Positioned as a potential therapeutic breakthrough for Cushing's syndrome, relacorilant is undergoing developmental stages aimed at addressing cortisol excess, with ongoing clinical trials demonstrating encouraging results. The company is also exploring the application of nab-paclitaxel in combination with relacorilant, targeting advanced ovarian tumors, thus broadening its portfolio in the oncology sphere.
Further reinforcing its commitment to innovation, Corcept Therapeutics is engaged in the development of selective cortisol modulators tailored for treating metastatic castration-resistant prostate cancer and combating antipsychotic-induced weight gain, among other related disorders. Additionally, the company is investing in FKBP5 gene expression assays, reflecting its dedication to pioneering diagnostic solutions in the field of endocrinology and beyond. Since its inception in 1998, Corcept Therapeutics has upheld a steadfast dedication to advancing the frontiers of medical science, with a strategic focus on enhancing patient outcomes through rigorous research and development initiatives.
With its headquarters strategically located in the heart of Silicon Valley, Corcept Therapeutics leverages its proximity to leading research institutions and a robust biotechnological ecosystem. This advantageous positioning not only facilitates collaborative opportunities but also underscores the company's pivotal role in driving forward transformative therapies that address unmet medical needs across diverse patient populations.
|
